Rallybio Corp RLYB
Rallybio Corp (Nasdaq: RLYB) is a hematology drug developer. Its lead program, RLYB116, is in Phase 1 for complement-mediated diseases (C5 inhibitor, once-weekly subcutaneous). Its next catalyst on record is Rallybio / Avenzo Therapeutics merger: Reverse merger closing and concurrent $215.0M financing (corporate event) (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Rallybio / Avenzo Therapeutics merger — Reverse merger closing and concurrent $215.0M financing (corporate event) (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| RLYB116 (C5 inhibitor) | complement dysregulation diseases (two Phase 1 healthy-volunteer trials plus confirmatory PK/PD Phase 1 completed 2025; data reported Q1 2026; no active trial disclosed) | protein/peptide | Phase 1 |
| RLYB332 (long-acting anti-matriptase-2 antibody) | diseases of iron overload | antibody | Pre-clinical |
| REV102 (ENPP1 inhibitor, sold to Recursion July 2025; company holds $5.0M Phase 1-dosing milestone and royalties) | hypophosphatasia | small molecule | Pre-clinical |
Recent results and decisions
- Jun 1, 2026positive AVZO-1418 Phase 1 monotherapy: 5 responders among 18 efficacy-evaluable patients and 4 of 10 in NSCLC; no Grade 3+ neutropenia at 4.5 mg/kg Q2W or below (data cut May 13, 2026).
In 18 efficacy evaluable patients, 9 remain on treatment including 5 responders
Filing - Jun 1, 2026positive AVZO-023 plus fulvestrant Phase 1 dose escalation: early efficacy signs at 100 mg BID with 5 of 6 patients still on treatment; 1 DLT at 100 mg BID.
AVZO-023 + Fulvestrant ORION-1 Phase 1 Dose-Escalation Encouraging Signs of Efficacy in HR+/HER2- Breast Cancer at 100 mg BID (N=6)
Filing - Mar 2, 2026positive Candid's Phase 1 myasthenia gravis study showed robust early responses in refractory patients (average QMG change -19.3 at 16 weeks in first dose group, MG-ADL -6.7), data as of Feb 2, 2026.
Early cohorts show robust and consistent clinical response in refractory patients
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.